IP Library › Granted Patent US 12,263,190
Granted Patent B2
US 12,263,190 · App. 17/292,363 · Granted Apr 1, 2025

Methods and combinations for treatment and T cell modulation

Inventors: Jens Hasskarl (Boudry, CH); Stanley R. Frankel (Summit, NJ); Michael Ports (Seattle, WA); Michael Pourdehnad (Summit, NJ); Heidi Jessup (Seattle, WA); Yue Jiang (Seattle, WA); Jim Shi Xiang Qin (Seattle, WA); Neha Soni (Seattle, WA); Melissa Works (Seattle, WA)
Assignee: Juno Therapeutics, Inc.
A61K35/28A61K39/4611A61K39/4631A61K39/464412A61K39/464417A61P35/02A61P43/00C07K16/2809C07K16/2866C07K16/2896C12N5/0636A61K2239/31A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,190
App. No.
17/292,363
Granted
Apr 1, 2025
Kind
B2
Abstract

The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

Claims (44)

1. A method of treatment, comprising:

(a) administering a T cell therapy to a subject having a cancer, said T cell therapy comprising a dose of T cells expressing a recombinant antigen receptor that binds to a target antigen; and

(b) administering to the subject an immunomodulatory compound, wherein the compound is(S) -3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

2. The method of claim 1 , wherein the immunomodulatory compound is administered at a dose of from or from about 0.1 mg to 5 mg per day.

3. The method of claim 1 , wherein the administration of the compound is initiated subsequently to initiation of administration of the T cell therapy.

4. The method of claim 3 , wherein the administration of the compound is initiated within or within about 90 days after initiation of administration of the T cell therapy.

5. The method of claim 1 , wherein the administration of the compound is initiated prior to administration of the T cell therapy.

6. The method of claim 5 , wherein the compound is administered from or from about 0 to 30 days prior to initiation of the T cell therapy.

7. The method of claim 1 , wherein the cancer is a B cell malignancy.

8. The method of claim 1 , wherein the subject is or has been identified as having an Eastern Cooperative Oncology Group Performance Status (ECOG) status of less than or equal to 1.

9. The method of claim 1 , wherein the target antigen is CD20, CD19, CD22, ROR1, CD45, CD21, CD5, CD33, Igkappa, Iglambda, CD79a, CD79b, or CD30.

10. The method of claim 1 , wherein the cancer is a lymphoma.

11. The method of claim 1 , wherein the target antigen is BCMA, G protein-coupled receptor class C group 5 member D (GPRC5D), CD38 (cyclic ADP ribose hydrolase), CD138 (syndecan-1, syndecan, SYN-1), CS-1 (CS1, CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24), BAFF-R, TACI, or FcRH5.

12. The method of claim 1 , wherein the cancer is a multiple myeloma.

13. The method of claim 1 , wherein the administration of the compound continues for a period that is greater than one month.

14. The method of claim 1 , wherein at the time of the initiation of the administration of the compound, the subject does not exhibit a severe toxicity following the administration of the T cell therapy.

15. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of(S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione.

16. The method of claim 1 , wherein the compound is (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione.

17. The method of claim 1 , wherein the compound is administered orally.

18. The method of claim 1 , wherein the administration of the compound comprises administration at an amount, frequency, and/or duration effective to:

(a) effect an increase in antigen-specific or antigen receptor-driven activity of naïve or non-exhausted T cells in the subject following exposure of the T cells to antigen or to an antigen receptor-specific agent as compared to the absence of said administration of said compound; or

(b) prevent, inhibit, or delay the onset of an exhaustion phenotype in naïve or non-exhausted T cells in the subject following exposure of the T cells to antigen or to an antigen receptor-specific agent, as compared to the absence of said administration of said compound; or

(c) reverse an exhaustion phenotype in exhausted T cells in the subject, as compared to the absence of said administration of said subject.

19. The method of claim 1 , wherein the recombinant antigen receptor is a chimeric antigen receptor that specifically binds the target antigen.

20. The method of claim 1 , wherein the dose of genetically engineered T cells comprises from or from about 1×105 to 5×108 total CAR-expressing T cells, inclusive.

21. The method of claim 1 , wherein the dose of cells is administered parenterally.

22. The method of claim 1 , wherein the T cells are primary T cells obtained from a subject.

23. The method of claim 1 , wherein the T cells are autologous to the subject.

24. The method of claim 1 , wherein the T cells are allogeneic to the subject.

25. The method of claim 1 , further comprising, immediately prior to the administration of the T cell therapy, administering a lymphodepleting therapy to the subject.

26. A kit comprising:

(a) a T cell therapy comprising a dose of T cells expressing a recombinant antigen receptor that binds to a target antigen; and

(b) an immunomodulatory compound selected from the group consisting of: thalidomide analogs; thalidomide derivatives; compounds that interact with and/or bind to cereblon (CRBN) and/or one or more members of the CRBN E3 ubiquitin-ligase complex; inhibitors of Ikaros (IKZF1); inhibitors of Aiolos (IKZF3); and compounds that enhance or promote ubiquitination, depletion, and/or degradation of Ikaros (IKZF1) and/or Aiolos (IKZF3); and

(c) instructions for administering the compound and/or the T cell therapy according to the methods of claim 1 .

27. The method of claim 1 , wherein the immunomodulatory compound is administered in an effective amount of from about 0.1 mg to about 1 mg.

28. The method of claim 1 , wherein the immunomodulatory compound is administered in an effective amount of about 0.4 mg, about 0.5 mg, about 0.7 mg, about 0.8 mg, and/or about 1.0 mg.

29. The method of claim 1 , wherein the immunomodulatory compound is administered daily for a period of time in a cycling regimen.

30. The method of claim 1 , wherein the immunomodulatory compound is administered once daily for 21 days over a 28-day treatment cycle.

31. The method of claim 1 , wherein the administration of the immunomodulatory compound continues for a period that extends for at or greater than three months, four months, five months, or six months.

32. The method of claim 1 , wherein the administration of the compound is initiated concurrently with initiation of administration of the T cell therapy.

33. The method of claim 25 , wherein the lymphodepleting therapy comprises:

administration of cyclophosphamide at about 200-400 mg/m 2 , inclusive, and/or fludarabine at about 20-40 mg/m 2 , daily for 2-4 days;

administration of cyclophosphamide at about 500 mg/m 2 ; or

administration of bendamustine.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2022
From: HASSKARL, JENS
To: CELGENE R&D SARL
Reel/Frame 058531/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2022
From: POURDEHNAD, MICHAEL; FRANKEL, STANLEY R.
To: CELGENE CORPORATION
Reel/Frame 058531/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2022
From: JESSUP, HEIDI; JIANG, YUE; PORTS, MICHAEL; QIN, JIM SHI XIANG; SONI, NEHA; WORKS, MELISSA
To: JUNO THERAPEUTICS, INC.
Reel/Frame 058531/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2022
From: CELGENE R&D SARL
To: JUNO THERAPEUTICS, INC.
Reel/Frame 058531/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2022
From: CELGENE CORPORATION
To: JUNO THERAPEUTICS, INC.
Reel/Frame 058531/0533 →
Continuity (3)
Provisional Application 62826928 · Mar 29, 2019
Provisional Application 62757755 · Nov 8, 2018
Related Publication 20220008477A1 · Jan 13, 2022
References Cited (400)
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4452773A · Molday · 1984 [cited by applicant]
US 4501728A · Geho et al. · 1985 [cited by applicant]
US 4690915A · Rosenberg · 1987 [cited by applicant]
US 4795698A · Owen et al. · 1989 [cited by applicant]
US 4837028A · Allen · 1989 [cited by applicant]
US 5019369A · Presant et al. · 1991 [cited by applicant]
US 5200084A · Liberti et al. · 1993 [cited by applicant]
US 5219740A · Miller et al. · 1993 [cited by applicant]
US 5635517A · Muller et al. · 1997 [cited by applicant]
US 5712291A · D'Amato · 1998 [cited by applicant]
US 5798368A · Muller et al. · 1998 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6207453B1 · Maass et al. · 2001 [cited by applicant]
US 6281230B1 · Muller et al. · 2001 [cited by applicant]
US 6316471B1 · Muller et al. · 2001 [cited by applicant]
US 6335349B1 · Muller et al. · 2002 [cited by applicant]
US 6380239B1 · Muller et al. · 2002 [cited by applicant]
US 6395754B1 · Muller et al. · 2002 [cited by applicant]
US 6403613B1 · Man et al. · 2002 [cited by applicant]
US 6410319B1 · Raubitschek et al. · 2002 [cited by applicant]
US 6451995B1 · Cheung et al. · 2002 [cited by applicant]
US 6458810B1 · Muller et al. · 2002 [cited by applicant]
US 6476052B1 · Muller et al. · 2002 [cited by applicant]
US 7070995B2 · Jensen · 2006 [cited by applicant]
US 7091353B2 · Robarge et al. · 2006 [cited by applicant]
US 7244759B2 · Muller et al. · 2007 [cited by applicant]
US 7265209B2 · Jensen · 2007 [cited by applicant]
US 7320991B2 · Figg et al. · 2008 [cited by applicant]
US 7354762B2 · Jensen · 2008 [cited by applicant]
US 7446179B2 · Jensen et al. · 2008 [cited by applicant]
US 7446190B2 · Sadelain et al. · 2008 [cited by applicant]
US 7446191B2 · Jensen · 2008 [cited by applicant]
US 8324353B2 · Jensen · 2012 [cited by applicant]
US 8339645B2 · Nakawaki · 2012 [cited by applicant]
US 8389282B2 · Sadelain et al. · 2013 [cited by applicant]
US 8479118B2 · Lindersay · 2013 [cited by applicant]
US 8716315B2 · Figg et al. · 2014 [cited by applicant]
US 8802374B2 · Jensen · 2014 [cited by applicant]
US 8822647B2 · Jensen · 2014 [cited by applicant]
US 8911993B2 · June et al. · 2014 [cited by applicant]
US 9221788B2 · Cohen et al. · 2015 [cited by applicant]
US 9629849B2 · Cohen et al. · 2017 [cited by applicant]
US 9765342B2 · Kochenderfer · 2017 [cited by applicant]
US 9828361B2 · Man et al. · 2017 [cited by applicant]
US 10080801B2 · Parikh et al. · 2018 [cited by applicant]
US 20020045643A1 · Muller et al. · 2002 [cited by applicant]
US 20020131960A1 · Sadelain et al. · 2002 [cited by applicant]
US 20030045552A1 · Robarge et al. · 2003 [cited by applicant]
US 20030096841A1 · Robarge et al. · 2003 [cited by applicant]
US 20030170238A1 · Gruenberg et al. · 2003 [cited by applicant]
US 20070116690A1 · Yang et al. · 2007 [cited by applicant]
US 20110003380A1 · Miltenyi et al. · 2011 [cited by applicant]
US 20130149337A1 · Cooper et al. · 2013 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140045843A1 · Schafer et al. · 2014 [cited by applicant]
US 20140046057A1 · Cohen et al. · 2014 [cited by applicant]
US 20140162282A1 · Schafer et al. · 2014 [cited by applicant]
US 20140271635A1 · Brogdon et al. · 2014 [cited by applicant]
US 20150283178A1 · June et al. · 2015 [cited by applicant]
US 20160017286A1 · Albelda et al. · 2016 [cited by applicant]
US 20160051530A1 · Thakurta et al. · 2016 [cited by applicant]
US 20160159768A1 · Man et al. · 2016 [cited by applicant]
US 20160313300A1 · Trotter et al. · 2016 [cited by applicant]
US 20170051035A1 · Payne et al. · 2017 [cited by applicant]
US 20180360880A1 · Brentjens et al. · 2018 [cited by applicant]
US 20190084924A1 · Traverse · 2019 [cited by applicant]
US 20200078404A1 · Ports et al. · 2020 [cited by applicant]
US 20220401483A1 · Ports et al. · 2022 [cited by applicant]
US 20230165872A1 · Ports et al. · 2023 [cited by applicant]
EP 0452342 · 1994 [cited by applicant]
EP 2537416 · 2012 [cited by applicant]
WO WO1992008796 · 1992 [cited by applicant]
WO WO1994028143 · 1994 [cited by applicant]
WO WO1996013593 · 1996 [cited by applicant]
WO WO1996018105 · 1996 [cited by applicant]
WO WO1998003502 · 1998 [cited by applicant]
WO WO1998054170 · 1998 [cited by applicant]
WO WO1999018129 · 1999 [cited by applicant]
WO WO1999060120 · 1999 [cited by applicant]
WO WO2000014257 · 2000 [cited by applicant]
WO WO2002059106 · 2002 [cited by applicant]
WO WO2002068414 · 2002 [cited by applicant]
WO WO2003020763 · 2003 [cited by applicant]
WO WO2004033685 · 2004 [cited by applicant]
WO WO2006000830 · 2006 [cited by applicant]
WO WO2008039489 · 2008 [cited by applicant]
WO WO2008154252 · 2008 [cited by applicant]
WO WO2009072003 · 2009 [cited by applicant]
WO WO2010033140 · 2010 [cited by applicant]
WO WO2010104949 · 2010 [cited by applicant]
WO WO2011044186 · 2011 [cited by applicant]
WO WO2011100380 · 2011 [cited by applicant]
WO WO2012129514 · 2012 [cited by applicant]
WO WO2013071154 · 2013 [cited by applicant]
WO WO2013123061 · 2013 [cited by applicant]
WO WO2013126726 · 2013 [cited by applicant]
WO WO2013166321 · 2013 [cited by applicant]
WO WO2014031687 · 2014 [cited by applicant]
WO WO2014055668 · 2014 [cited by applicant]
WO WO2015105522 · 2015 [cited by applicant]
WO WO2016014530 · 2016 [cited by applicant]
WO WO2016014789 · 2016 [cited by applicant]
WO WO2016046724 · 2016 [cited by applicant]
WO WO2016090320 · 2016 [cited by applicant]
WO WO2016090327 · 2016 [cited by applicant]
WO WO2016094304 · 2016 [cited by applicant]
WO WO2016164580 · 2016 [cited by applicant]
WO WO2016187349 · 2016 [cited by applicant]
WO WO2016210129 · 2016 [cited by applicant]
WO WO2016210262 · 2016 [cited by applicant]
WO WO2017025038 · 2017 [cited by applicant]
WO WO2017058754 · 2017 [cited by applicant]
WO WO2017096024 · 2017 [cited by applicant]
WO WO2017173256 · 2017 [cited by applicant]
WO WO2017176289 · 2017 [cited by applicant]
WO WO2017214207 · 2017 [cited by applicant]
WO WO2018023100 · 2018 [cited by applicant]
WO WO2018071873 · 2018 [cited by applicant]
WO WO2018085690 · 2018 [cited by applicant]
WO WO2018085731 · 2018 [cited by applicant]
WO WO2018093591 · 2018 [cited by applicant]
WO WO2018102785 · 2018 [cited by applicant]
WO WO2018102786 · 2018 [cited by applicant]
WO WO2018102787 · 2018 [cited by applicant]
WO WO2018075820 · 2018 [cited by examiner]
WO WO2018183842 · 2018 [cited by applicant]
WO WO2018204427 · 2018 [cited by applicant]
WO WO2018223101 · 2018 [cited by applicant]
WO WO2019014100 · 2019 [cited by applicant]
WO WO2019108900 · 2019 [cited by applicant]
WO WO2019109053 · 2019 [cited by applicant]
WO WO2019226761 · 2019 [cited by applicant]
WO WO2020014333 · 2020 [cited by applicant]
WO WO2020092848 · 2020 [cited by applicant]
WO WO2020097403 · 2020 [cited by applicant]
WO WO2020210418 · 2020 [cited by applicant]
WO WO2021091978 · 2021 [cited by applicant]
WO WO2021092498 · 2021 [cited by applicant]
WO WO2021222330 · 2021 [cited by applicant]
WO WO2022212384 · 2022 [cited by applicant]
WO WO2022221726 · 2022 [cited by applicant]
US 8,252,592 B2, 08/2012, Sadelain (withdrawn) [cited by applicant]
Brittain, “X-ray Diffraction III: Pharmaceutical Applications of X-ray Powder Diffraction,” Spectroscopy (2001) 16(7):14-18, p. 15. [cited by applicant]
U.S. Appl. No. 18/284,800, filed Mar. 29, 2022, by Trede et al. (Copy not provided). Copy not submitted herewith pursuant to the waiver of 37 C.F. R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Anonymous, “Safety and Efficacy of bb2121 (lde-cel) Combinations in Multiple Myeloma-Full Text View-ClinicalTrials.gov”, Apr. 22, 2021, XP055952059, 12 pages. [cited by applicant]
Brahmandam et al. “106 Treatment with CC-99282 enhances antitumor function of the anti-CD19 Car T cell therapy lisocabtagene maraleucel (liso-cel).” J Immunother Cancer (2021) 9(Suppl 2):A117, 1 page. [cited by applicant]
Database PUBCHEM: Golcadeomide hydrochloride, XP055938424, Database Accession No. 163203519, Created May 12, 2022, 10 pages. [cited by applicant]
Legarda et al., “Recent Advances in the Treatment of Patients with Multiple Myeloma,” Cancers (Basel). (2020) 12(12):3576, 22 pages. [cited by applicant]
Li et al. “PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.” [cited by applicant]
Li et al., “Mechanisms of failure of chimeric antigen receptor T-cell therapy,” Curr Opin Hematol. (Nov. 2019);26(6):427-433. [cited by applicant]
Lopez-Girona et al., “CC-92480 is a Novel Cerebion E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells,” Blood (2019) 134 (Supplement_1): 18… [cited by applicant]
Maude et al., “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia,” N Engl J Med (2018) 378(5):439-448. [cited by applicant]
Michot et al. “Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL)-First Results from a P… [cited by applicant]
Munshi et al., “Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma,” N Engl J Med (2021) 384(8):705-716. [cited by applicant]
Qin et al, “Treatment with Iberdomide Enhances Antitumor Function of the Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel),” Cancer-Immunotherapy (2020) 28: 4S1: Abstract 1158,… [cited by applicant]
Qin et al, “Treatment with Iberdomide Enhances Antitumor Function of the Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel),” Poster: Presented at the 23rd Annual Meeting of the… [cited by applicant]
Raje et al. “KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myelo… [cited by applicant]
Steiner et al., “CAR-T cells in multiple myeloma: current status,” Magazine of European Medical Oncology. (2020) 13:43-49. [cited by applicant]
Abramson et al., “High CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (Transcend NHL 001),” Presented at 14th International Conference on Malignant Lymph… [cited by applicant]
Abramson et al., “High Durable CR Rates in R/R Aggressive B-NHL Treated with JCAR017 (Transcend NHL 001): Defined Composition CD19-Directed CAR T Cell Product Allows for Dose Finding and Definition of Pivotal Cohort,” P… [cited by applicant]
Abramson et al., “High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR 017 (Transcend NHL001): Defined Composition Allows for Dose-Finding and Defini… [cited by applicant]
Abramson et al., “Transcend NHL 001: Immunotherapy with the CD19-directed CAR T-cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,” Blood (2016) 128:4192 … [cited by applicant]
Actemra [Package Insert]. South San Francisco, CA: Genentech Inc, a Member of the Roche Group. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125276s127,125472s040lbl.pdf. [cited by applicant]
Actemra® [Prescribing Information]. South San Francisco, USA: Genentech Inc. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf. [cited by applicant]
Alonso-Camino et al., “CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors,” Mol Ther Nucleic Acids (2013) 2(5):e93. [cited by applicant]
Amatangelo et al. “Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitr… [cited by applicant]
Amatangelo et al. “PF559 Iberdomide (CC-220) is Pharmacodynamically Active and Has Dose-Dependent Immunostimulatory Activity in Relapsed/Refractory Multiple Myeloma Patients Irrespective of Prior Imid Drug Treatment.” [cited by applicant]
Attal et al. “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open… [cited by applicant]
Avet-Loiseau et al. “Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus d… [cited by applicant]
Balaian et al., “Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q,” Ann Hematol. (2016) 95(11): 1805-10. [cited by applicant]
Barrett et al., “Chimeric Antigen Receptor Therapy for Cancer,” Annual Review of Medicine (2014) 65:333-347. [cited by applicant]
Benedetti et al. “OP0204 Emapalumab, an interferon gamma (IFN-Y)-Blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA).” (2019): 1… [cited by applicant]
Bertilaccio et al., “Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo,” Blood (2013) 122:4171. [cited by applicant]
Bjorklund et al. “CC-122 is a cereblon modulating agent that is active in lenalidomide-resistant and lenalidomide/dexamethasone-double-resistant multiple myeloma pre-clinical models.” [cited by applicant]
Bjorklund et al. “Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide-and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.” [cited by applicant]
Bjorklund et al. “Rate of CRL4 CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.” [cited by applicant]
Boris-Lawrie et al., “Recent advances in retrovirus vector technology,” Current Opinion in Genetics & Development (1993) 3(1):102-109. [cited by applicant]
Botta et al. “Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.” [cited by applicant]
Brash et al., “Strontium phosphate transfection of human cells in primary culture: stable expression of the simian virus 40 large-T-antigen gene in primary human bronchial epithelial cells,” Mol. Cell Biol. (1987) 7: 20… [cited by applicant]
Brentjens et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Sci Transl Med. (2013) 5(177):177ra38. [cited by applicant]
Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood (2011) 118(18):4817-4828. [cited by applicant]
Bringhen et al. “Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.” [cited by applicant]
Brudno et al., “Toxicities of chimeric antigen receptor T cells: recognition and management.” [cited by applicant]
Buenrostro et al., “Transposition of Native Chromatin for Fast and Sensitive Epigenomic Profiling of Open Chromatin, DNA-binding Proteins and Nucleosome Position,” Nat Methods (2013) 10(12):1213-1218. [cited by applicant]
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,” Proc. Natl. Acad. Sci. USA (1… [cited by applicant]
Busch et al., “Role of memory T cell subsets for adoptive immunotherapy,” Semin Immunol (2016) 28(1):28-34. [cited by applicant]
Busch et al., “Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients,” Clin Exp Immunol. (2014) 177(2): 439-453. [cited by applicant]
Cairo et al., “Tumour lysis syndrome: new therapeutic strategies and classification,” Br J Haematol (2004) 127(1):3-11. [cited by applicant]
Carlens et al., “Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution,” Exp Hematol (2000) 28(10): 1137-1146. [cited by applicant]
Carpenter et al., “B-cell maturation antigen is a promising target for adoptive T-cell therapy of Multiple Myeloma,” Clin Cancer Res (2013) 19(8):2048-2060. [cited by applicant]
Carrillo et al., “The Multiple Sequence Alignment Problem in Biology,” Siam J Appl Math (1988) 48(5):1073-1082. [cited by applicant]
Cavaletti et al., “Chemotherapy-induced peripheral neurotoxicity,” Nature Reviews Neurology (2010) 6:657-666. [cited by applicant]
Cavalieri et al., “Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence,” Blood (2003) 102(2): 497-505. [cited by applicant]
Challita et al., “Multiple Modifications in Cis Elements of the Long Terminal Repeat of Retroviral Vectors Lead to Increased Expression and Decreased DNA Methylation in Embryonic Carcinoma Cells,” J Virol (1995) 69(2): … [cited by applicant]
Chamberlain et al. “Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.” [cited by applicant]
Chari et al. “Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.” [cited by applicant]
Chari et al. “Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.” [cited by applicant]
Cheadle et al., “Chimeric antigen receptors for T-cell based therapy,” Methods Mol Biol. (2012);907:645-66. [cited by applicant]
Chervin et al., “Engineering higher affinity T cell receptors using a T cell display system,” J Immunol Methods (2008) 339(2):175-184. [cited by applicant]
Cheson et al., “Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification,” J Clin Oncol (2014) 20(27):3059-3068. [cited by applicant]
Chicaybam et al., “An efficient low cost method for gene transfer to T lymphocytes,” PLoS One (2013) 8(3): e60298. [cited by applicant]
Cho et al., “A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression,” J Immunol (2015) 195:4822-4831. [cited by applicant]
Chothia et al., “The outline structure of the T-cell alpha beta receptor,” EMBO J (1988) 7(12):3745-3755. [cited by applicant]
Clambey et al., “The Ikaros Transcription Factor Regulates Responsiveness to IL-12 and Expression of IL-2 Receptor Alpha in Mature, Activated CD8 T Cells,” PLOS One, (2013) 8(2): e57435. [cited by applicant]
Clinicaltrials.gov Identifier NCT02315612. First posted Dec. 12, 2014. Last updated Oct. 9, 2019. [cited by applicant]
Cohen et al., “Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR,” J Immunol. (2005) 175:5799-5808. [cited by applicant]
Collins et al., “Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway,” Biochem J. (2017) 474(7): 1127-1147. [cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood (2003) 101:1637-1644. [cited by applicant]
Corral et al. “Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α.” [cited by applicant]
Couzin et al., “As Gelsinger case ends, gene therapy suffers another blow.” (2005): 1028-1028. [cited by applicant]
Cowan et al. “Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma.” (2019): 20… [cited by applicant]
Crayne et al. “The immunology of macrophage activation syndrome.” Frontiers in immunology 10 (2019): 119. [cited by applicant]
Crump et al., “Outcomes in refractory diffuse large B-cell lymphoma: results from the international Scholar-1 study,” Blood (2017) 130(16):1800-1808. [cited by applicant]
Darzalex Faspro™. [Package Insert]. Horsham, PA: Janssen Biotech, Inc; 2020. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf. [cited by applicant]
Darzalex®. [Package Insert]. Horsham, PA: Janssen Biotech, Inc; 2020. Available from: https://www.janssenmd.com/pdf/darzalex/darzalex_pi.pdf. [cited by applicant]
Davies et al. “Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.” [cited by applicant]
Davila et al., “CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia,” PLOS One (2013) 8(4):e61338. [cited by applicant]
Davila et al., “Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia,” Sci Transl Med (2014) 6:224ra25. [cited by applicant]
Davila et al., “How do CARs work?: Early insights from recent clinical studies targeting CD19,” Oncoimmunology (2012) 1(9):1577-1583. [cited by applicant]
De Felipe et al., “Targeting of Proteins Derived from Self-Processing Polyproteins Containing Multiple Signal Sequences,” Traffic (2004) 5(8):616-626. [cited by applicant]
De Felipe, “Skipping the co-expression problem: the new 2A “Chysel” technology,” Genet Vaccines Ther (2004) 2:13. [cited by applicant]
Deniger et al., “A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.” Clin Cancer Res. Jan. 2017; 23(2): 351-362. [cited by applicant]
Dimopoulos et al. “Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Endeavor): a randomised, phase 3, open-label, multicentre study.” [cited by applicant]
Dimopoulos et al. “Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.” [cited by applicant]
Dimopoulos et al. “Pomalidomide+ Bortezomib+ low-dose dexamethasone vs bortezomib+ low-dose dexamethasone as second-line treatment in patients with lenalidomide-pretreated multiple myeloma: a subgroup analysis of the ph… [cited by applicant]
Donahue et al. “Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.” The Journal of experimental medicine 176.4 (1992): 1125-1135. [cited by applicant]
Dudley et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science (2002) 298(5594):850-854. [cited by applicant]
Dumortier et al. “Ikaros regulates neutrophil differentiation.” [cited by applicant]
Durie et al. “A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.” [cited by applicant]
Even et al. “Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).” (2017): 6024-6024. [cited by applicant]
Facon et al. “Daratumumab in combination with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma (RRMM) patients with 2 prior lines of therapy: updated analysis of MMY1001.” (2017): 1824-1824. [cited by applicant]
Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine (2013) 5(215):215ra172. [cited by applicant]
Ferguson et al. “Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.” [cited by applicant]
Fischer et al. “Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.” [cited by applicant]
Fraietta et al., “Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.” Blood. Mar. 3, 2016;127(9):1117-27. [cited by applicant]
Frey et al. “Cytokine release syndrome with chimeric antigen receptor T cell therapy.” Biology of Blood and Marrow Transplantation 25.4 (2019): e123-e127. [cited by applicant]
Frey. “Cytokine release syndrome: who is at risk and how to treat.” [cited by applicant]
Gandhi et al. “Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN.” [cited by applicant]
Gandhi et al. “Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.” [cited by applicant]
Gardner et al., “Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults,” Blood (2017) 129(25):3322-3331. [cited by applicant]
Gattinoni et al., “Moving T memory stem cells to the clinic,” Blood. 2013 121(4): 567-568. [cited by applicant]
Godin et al., “Microfluidics and photonics for Bio-System-on-a-Chip: a review of advancements in technology towards a microfluidic flow cytometry chip,” J Biophotonics (2008) 1(5):355-376. [cited by applicant]
Gorgun et al., “Immunomodulatory Effects of Lenalidomide and Pomalidomide on Interaction of Tumor and Bone Marrow Accessory Cells in Multiple Myeloma,” Blood (2010) 116(17): 3227-3237. [cited by applicant]
Greipp et al. “International staging system for multiple myeloma.” [cited by applicant]
Grupp et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” N. Engl. J. Med. (2013) 368:1509-1518. [cited by applicant]
Gust et al. “Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.” [cited by applicant]
Hacein-Bey-Abina et al. “LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.” [cited by applicant]
Hagner et al., “CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL,” Blood (2015) 126(6):770-789. [cited by applicant]
Han et al., “Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges,” J Hematology & Oncology (2013) 6:47. [cited by applicant]
Haslett et al., “Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset,” J Exp Med. (1998) 187(11):1885-1892. [cited by applicant]
Hay et al. “Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.” [cited by applicant]
Heipel et al., “Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017,” Blood (2017) 130 (Suppl 1):2835. [cited by applicant]
Herman et al., “The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia,” Clin Cancer Res. (2017)23: 2831-2841. [cited by applicant]
Holler et al., “In vitro evolution of a T cell receptor with high affinity for peptide/MHC,” PNAS (2000) 97(10):5387-5392. [cited by applicant]
Holler et al., “TCRs with high affinity for foreign pMHC show self-reactivity,” Nat Immunol (2003) 4(1):55-62. [cited by applicant]
Howlader et al., SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on Nov. 2019 SEER data submission, posted to the SEER web site, Apr. 2020. [cited by applicant]
Huang et al., “DNA transposons for modification of human primary T lymphocytes,” Methods Mol Biol (2009) 506:115-126. [cited by applicant]
Hudecek et al., “Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells,” Clin Cancer Res (2013) 19(12):3153-3164. [cited by applicant]
Hudecek et al., “The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity,” Cancer Immunol Res (2015) 3(2):125-135. [cited by applicant]
Ito et al., “Identification of a primary target of thalidomide teratogenicity,” Science (2010) 327(5971): 1345-50. [cited by applicant]
Janeway et al., Immunobiology: The Immune System in Health and Disease, 3rd ED., Current Biology Publications (1997), p. 4:33. [cited by applicant]
Jensen et al., “Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans,” Biol Blood Marrow Transplant (… [cited by applicant]
Jessup et al., “Avadomide (CC-122) Improves Effector Function and Reverses Exhaustion in Chronically Stimulated Lisocabtagene Maraleucel (JCAR017) Drug Product,” Immunology (2019) Abstract 2320. [cited by applicant]
Jessup et al., “Avadomide (CC-122) Improves Effector Function and Reverses Exhaustion in Chronically Stimulated Lisocabtagene Maraleucel (JCAR017) Drug Product,” Poster 2320, Presented at the 2019 AACR Annual Meeting; M… [cited by applicant]
Jiang et al., “T-cell exhaustion in the tumor microenvironment,” Cell Death Dis (2015) 6:e1792. [cited by applicant]
Johnston, “Biolistic transformation: microbes to mice,” Nature (1990) 346:776-777. [cited by applicant]
Jores et al., “Resolution of hypervariable regions in T-cell receptor beta chains by a modified Wu-Kabat index of amino acid diversity.,” PNAS (1990) 87(23):9138-9142. [cited by applicant]
Kalos et al., “T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia,” Sci Transl Med (2011) 3(95):95ra73. [cited by applicant]
Karakike et al. “Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis.” [cited by applicant]
Kawano, et al. “Targeting the bone marrow microenvironment in multiple myeloma.” [cited by applicant]
Khalil et al., “The Future of Cancer Treatment: Immunomodulation, CARs and Combination Therapy.” Nat. Rev. Clin. Oncol. Mar. 2016; 13(5): 273-290. [cited by applicant]
Klebanoff et al., “Sorting through subsets: Which T cell populations mediate highly effective adoptive immunotherapy?” J Immunother (2012) 35(9):651-660. [cited by applicant]
Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood (2012) 119:2709-2720. [cited by applicant]
Kochenderfer et al., “Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor,” J Clin … [cited by applicant]
Kochenderfer et al., “Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor,” J. Immunotherapy (2009) 32(7): 689-702. [cited by applicant]
Kochenderfer et al., “Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors,” Nat Rev Clin Oncol (2013) 10(5):267-276. [cited by applicant]
Koste et al., “T-cell receptor transfer into human T cells with ecotropic retroviral vectors,” Gene Therapy (2014) 21:533-538. [cited by applicant]
Kotb et al., “Bacterial pyrogenic exotoxins as superantigens,” Clinical Microbiology Reviews (1995) 8:411-426. [cited by applicant]
Kotla et al., “Mechanism of action of lenalidomide in hematological malignancies.” J Hematol Oncol. (2009) 2:36. [cited by applicant]
Krejcik et al. “Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.” [cited by applicant]
Kronke et al., “Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells,” Science (2014) 343(6168):301-305. [cited by applicant]
Kronke et al., “Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS,” Nature. (2015) 523(7559): 183-188. [cited by applicant]
Kumar et al. “Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma.” [cited by applicant]
Kumar et al. “International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.” [cited by applicant]
Kumar et al. “Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.” [cited by applicant]
Kumar, et al. “Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.” [cited by applicant]
Kuramitsu et al., “Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses,” Cancer Gene Therapy (2015) 22(10):487-49… [cited by applicant]
Kurucz et al., “A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor,” PNAS (1993) 90(9):3830-3834. [cited by applicant]
Lamers et al., “Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells,” Blood (2011) 117(1):72-82. [cited by applicant]
Landgren et al. “Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.” Bone marrow transplantation 51.12 (2016): 1565-1568. [cited by applicant]
Larocca et al. “Emerging drugs and combinations to treat multiple myeloma.” [cited by applicant]
Laurent et al. “γ-Secretase directly sheds the survival receptor BCMA from plasma cells.” [cited by applicant]
Lee et al., “A predictive probability design for phase II cancer clinical trials.” [cited by applicant]
Lee et al. “ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.” [cited by applicant]
Lee et al. Bayesian efficacy monitoring via predictive probability. PID:901;v1.1.1.1. 2019b. Available from: https://trialdesign.org/one-page-shell.html#BEMPR. [cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood. (2014) 124(2):188-95. [cited by applicant]
Lee et al., “Evaluation of B Cell Maturation Antigen as a Target for Antibody Drug Conjugate Mediated Cytotoxicity in Multiple Myeloma,” Br J Haematol (2016) 174(6): 911-22. [cited by applicant]
Lee et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and yound adults: a phase 1 dose escalation trial,” The Lancet (2015) 385(9967): 517-528. [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol (2003) 27(1):55-77. [cited by applicant]
Lehmberg, et al. “Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.” [cited by applicant]
Leleu et al. “Role of proteasome inhibitors in relapsed and/or refractory multiple myeloma.” [cited by applicant]
Li et al. “Murine leukemia induced by retroviral gene marking.” [cited by applicant]
Li et al., “Directed evolution of human T-cell receptors with picomolar affinities by phage display,” Nat Biotechnol (2005) 23(3):349-354. [cited by applicant]
Ling et al. (1987). “Leucocyte typing III,” 302. [cited by applicant]
Liu et al. “Bayesian optimal interval designs for phase I clinical trials.” [cited by applicant]
Liu et al., “Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy,” Nat Biotechnol (2016) 34(4):430-434. [cited by applicant]
Locke et al. “Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL).” (2017): 1547-1547. [cited by applicant]
Locke et al., “Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with a… [cited by applicant]
Lonial et al. “Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.” [cited by applicant]
Lonial et al. “Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.” [cited by applicant]
Lonial et al. “Elotuzumab therapy for relapsed or refractory multiple myeloma.” [cited by applicant]
Lonial et al. “First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).” (2019): 8006-8006. [cited by applicant]
Lonial et al. “Translational and clinical evidence of a differentiated profile for the novel CELMoD, iberdomide (CC-220).” (2019): 3119-3119. [cited by applicant]
Lopez-Girona et al., “Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide,” Leukemia. (2012) 26(11): 2326-35. [cited by applicant]
Lu et al. “The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.” [cited by applicant]
Lupton et al., “Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene,” Mol and Cell Biol (1991) 11(6):3374-3378. [cited by applicant]
Maloney et al., “Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration,” Blood (2017) 13… [cited by applicant]
Maloney et al., “Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 (lisocabtagene maraleucel; liso-cel) in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Adminis… [cited by applicant]
Manuri et al., “piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies,” Hum Gene Ther (2010) 21(4):427-437. [cited by applicant]
Martin et al., “Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma.” HemaSphere https://doi. org/10.1097/… [cited by applicant]
Matyskiela et al. “A cereblon modulator (CC-220) with improved degradation of Ikaros and Alolos.” Journal of medicinal chemistry 61.2 (2018): 535-542. [cited by applicant]
Maude et al. “Managing cytokine release syndrome associated with novel T cell-engaging therapies.” [cited by applicant]
Maude et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” N Engl J Med. Oct. 16, 2014;371(16):1507-17. [cited by applicant]
McDaniel, J.M., “Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation.” Ph.D. Dissertation, University of South Florida, Aug. 24, 2012, Retrieved from https://scholarcommons.usf.edu/cgi/vi… [cited by applicant]
McGarrity et al. “Patient monitoring and follow-up in lentiviral clinical trials.” [cited by applicant]
Miller et al., “Improved retroviral vectors for gene transfer and expression,” Biotechniques (1989) 7(9):980-990. [cited by applicant]
Miller, “Retrovirus packaging cells,” Hum Gene Ther (1990) 1(1):5-14. [cited by applicant]
Millrine et al., “A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders,” Trends Mol Med. Apr. 2017;23(4):348-361. [cited by applicant]
Mitsiades, et al. “Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.” [cited by applicant]
Modlich et al. “Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.” [cited by applicant]
Moreau et al. “Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” [cited by applicant]
Moreau et al. “Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.” [cited by applicant]
Mullen et al., “Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system,” Proc Natl Acad Sci U.S.A (1992) 89:33-37. [cited by applicant]
Munshi et al. “Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.” (2020): 8503-8503. [cited by applicant]
Muranski et al., “Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?” Nat Clin Pract Oncol (2006) 3(12):668-681. [cited by applicant]
Neelapu et al. “Chimeric antigen receptor T-cell therapy-assessment and management of toxicities.” [cited by applicant]
Neelapu et al., “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B- Cell Lymphoma,” N Engl J Med (2017) 377(26):2531-2544. [cited by applicant]
Nijhof et al. “Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib.” [cited by applicant]
Nooka et al. “Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.” [cited by applicant]
Oken et al., “Toxicity and response criteria of the Eastern Cooperative Oncology Group,” Am J Clin Oncol (1982) 5(6):649-655. [cited by applicant]
Oshima et al., “Immunomodulatory drugs (IMiDs),” Nihon Rinsho. (2014) 72(6): 1130-5. [cited by applicant]
Otahal et al., “Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells,” Oncoimmunology (2015) 5(4):e1115940. [cited by applicant]
Overdijk et al. “Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.” mAbs (2015) 7(2):311-320. [cited by applicant]
Paiva et al. “The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.” [cited by applicant]
Palumbo et al. “Daratumumab, bortezomib, and dexamethasone for multiple myeloma.” [cited by applicant]
Park et al., “Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma,” Mol Ther (2007) 15(4):825-833. [cited by applicant]
Park et al., “Treating cancer with genetically engineered T cells,” Trends Biotechnol (2011) 29(11):550-557. [cited by applicant]
Park. Managing cytokine release syndrome [slides]. Clinical Care Options Oncol. 2017. Available from: https://www.clinicaloptions.com/oncology/programs/managing-aes/modules/managing-_crs_slides. [cited by applicant]
Parkhurst et al., “Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.” Clin Cancer Res. (2009) 15:169-180. [cited by applicant]
Pomalyst®. [Package Insert]. Summit, NJ: Celgene Corporation;2019. [cited by applicant]
Pont et al. “γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.” [cited by applicant]
Porter et al., “Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia,” Sci Transl Med (2015) 7(303):303ra139. [cited by applicant]
Quach et al., “Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.” Leukemia. 2010 24(1):22-32. [cited by applicant]
Raje et al. “Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.” [cited by applicant]
Rajkumar et al., “Multiple myeloma: diagnosis and treatment.” Mayo Clinic Proceedings (2016) 91(1):101-119. [cited by applicant]
Ramos-Casals et al. “Adult haemophagocytic syndrome.” [cited by applicant]
Ramsay et al., “Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism i… [cited by applicant]
Ramsborg et al., “JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 Car T Cell to Patients with NHL,” Blood (2017) 130(Suppl_1):4471. [cited by applicant]
Ramsborg et al., “JCAR017(lisocabtagene maraleucel; liso-cel) is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cells to Patients With NHL,” Po… [cited by applicant]
Reddy et al. “Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.” [cited by applicant]
Reeder et al. “Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.” [cited by applicant]
Richardson et al. “Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.” [cited by applicant]
Richardson et al. “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.” [cited by applicant]
Riddell et al., “Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant,” Human Gene Therapy (199… [cited by applicant]
RoActemra® [Summary of Product Characteristics]. Welwyn Garden City, United Kingdom: Roche Products Limited, 2019. [cited by applicant]
Rosenberg et al., “Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy,” Clin Cancer Res (2011) 17(13):4550-4557. [cited by applicant]
Rosenberg, “Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know,” Nat Rev Clin Oncol (2011) 8(10):577-585. [cited by applicant]
Rothe et al. “Biosafety challenges for use of lentiviral vectors in gene therapy.” [cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor (CAR) design,” Cancer Discov (2013) 3(4):388-398. [cited by applicant]
Sanchez et al. “The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma.” [cited by applicant]
San-Miguel et al. “Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double… [cited by applicant]
San-Miguel et al., New approaches to myeloma treatment in 2017. Hematology Education: the Education Program for the Annual Congress of the European Hematology Association. (2017)11(1):9-12. [cited by applicant]
Savoldo et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” J Clin Invest (2011) 121(5):1822-1826. [cited by applicant]
Scarpa et al., “Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines,” Virology (1991) 180(2):849-852. [cited by applicant]
Schlueter et al., “Specificity and Binding Properties of a Single-chain T Cell Receptor,” J Mol Biol (1996) 256(5):859-869. [cited by applicant]
Scholler et al. “Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.” [cited by applicant]
Schuler et al., “SYFPEITHI: database for searching and T-cell epitope prediction,” Methods Mol Biol. (2007) 409: 75-93. [cited by applicant]
Schulert et al. “Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies.” [cited by applicant]
Schuster et al. “Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma.” Blood (2017) 130(Supplement 1):577. [cited by applicant]
Seckinger et al. “Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment.” [cited by applicant]
Sharma et al., “Efficient Sleeping Beauty DNA Transposition From DNA Minicircles,” Molec Ther Nucl Acids (2013) 2:e74. [cited by applicant]
Siddiqi et al., “Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted Car T Cell Product, JCAR017,” Oral Presen… [cited by applicant]
Siddiqi, et al. Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted Car T Cell Product, JCAR017. Presented at … [cited by applicant]
Siegel et al. “Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.” [cited by applicant]
Siegel et all. “Cancer statistics, 2020.” [cited by applicant]
Singh et al., “ProPred: prediction of HLA-DR binding sites,” Bioinformatics (2001) 17(12):1236-1237. [cited by applicant]
Sommermeyer et al., “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo,” Leukemia (2016) 30(2):492-500. [cited by applicant]
Song et al. “Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.” [cited by applicant]
Soni et al. “Iberdomide Increases the Potency of the Anti-BCMA CAR T Cell Product Orvacabtagene Autoleucel (Orva-Cel).” Molecular Therapy. vol. 28. No. 4. 50 Hampshire St, Floor 5, Cambridge, MA 02139 USA: Cell Press, 2… [cited by applicant]
Sonneveld et al. “How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?.” [cited by applicant]
Soo Hoo et al., “Characterization of a single-chain T-cell receptor expressed in [cited by applicant]
Stewart et al. “Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.” [cited by applicant]
Swerdlow et al., “The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms,” Blood (2016) 127(20): 2375-2390. [cited by applicant]
Szoka et al., “Comparative properties and methods of preparation of lipid vesicles (liposomes),” Annu Rev Biophys Bioeng. (1980) 9:467-508. [cited by applicant]
Teachey et al. “Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.” [cited by applicant]
Terakura et al., “Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells,” Blood (2012) 119(1):72-82. [cited by applicant]
Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nat Biotechnol (2013) 31(10):928-933. [cited by applicant]
Thompson et al. “Markers of initial and long-term responses to idecabtagene vicleucel (lde-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma.” (2019): 4328-4328. [cited by applicant]
Tsukahara et al., “CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models,” Biochem Biophys Res Commun (2013) 438(1):84-89. [cited by applicant]